- Raw materials
- Barbiturates
- Vinylbital
Vinylbital API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Vinylbital | CAS No: 2430-49-1 | GMP-certified suppliers
A medication that acts as a central nervous system depressant with sedative and hypnotic properties, primarily researched for managing anxiety, insomnia, and related neurological conditions.
Therapeutic categories
Product Snapshot
- Vinylbital is an oral small molecule barbiturate formulation
- It is primarily used for its sedative and hypnotic effects in therapeutic applications
- The compound is currently in an experimental approval status with no established regulatory approvals
Clinical Overview
Although specific clinical indications for Vinylbital are not well-defined, barbiturates generally function as central nervous system depressants. Their mechanism of action typically involves modulation of gamma-aminobutyric acid type A (GABA_A) receptors, enhancing GABAergic inhibitory neurotransmission, which results in sedation, hypnosis, and anxiolysis.
Pharmacokinetic and metabolic data for Vinylbital remain sparse. In barbiturate compounds, critical absorption, distribution, metabolism, and excretion (ADME) parameters usually include high oral bioavailability, extensive hepatic metabolism primarily via cytochrome P450 enzymes, and renal excretion of metabolites. Due to its experimental status, Vinylbital’s specific ADME profile has not been fully elucidated.
From a safety and toxicity perspective, barbiturates carry risks of respiratory depression, dependence, tolerance, and potential for overdose toxicity. Without detailed clinical safety data on Vinylbital, caution is warranted in considering its pharmacological effects and toxicological profile, aligning with general barbiturate safety concerns.
Vinylbital has not achieved widespread regulatory approval and remains an experimental compound. Consequently, it is not commonly associated with marketed pharmaceutical products or established therapeutic regimens.
When sourcing Vinylbital as an active pharmaceutical ingredient, ensuring compliance with quality standards and regulatory guidelines is critical. Procurement should involve thorough verification of supplier certifications, purity specifications, batch-to-batch consistency, and adherence to Good Manufacturing Practices (GMP) to support potential research and development activities.
Identification & chemistry
| Generic name | Vinylbital |
|---|---|
| Molecule type | Small molecule |
| CAS | 2430-49-1 |
| UNII | 3W58ITX06Q |
| DrugBank ID | DB13770 |
Formulation & handling
- Vinylbital is a small molecule barbituric acid derivative suitable primarily for oral formulation.
- Its moderate water solubility and LogP indicate potential for balanced absorption and formulation flexibility.
- No specific peptide or biologic stability concerns are noted, but standard precautions for barbiturate derivatives apply.
Regulatory status
Vinylbital is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
